Fingerprint Dive into the research topics where Cancer Institute of New Jersey (CINJ), Gynecology/Oncology is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Ovarian Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Tumors Chemical Compounds
Therapeutics Medicine & Life Sciences
HIV Reverse Transcriptase Medicine & Life Sciences
Single Nucleotide Polymorphism Medicine & Life Sciences
Endometrial Neoplasms Medicine & Life Sciences
RNA-Directed DNA Polymerase Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1987 2019

  • 2619 Citations
  • 27 h-Index
  • 56 Article
  • 6 Review article
  • 3 Chapter
  • 1 Letter

Association between genetically predicted polycystic ovary syndrome and ovarian cancer: A Mendelian randomization study

Harris, H. R., Cushing-Haugen, K. L., Webb, P. M., Nagle, C. M., Jordan, S. J., Risch, H. A., Rossing, M. A., Doherty, J. A., Goodman, M. T., Modugno, F., Ness, R. B., Moysich, K. B., Kjær, S. K., Høgdall, E., Jensen, A., Schildkraut, J. M., Berchuck, A., Cramer, D. W., Bandera, E. V., Rodriguez, L. & 10 others, Wentzensen, N., Kotsopoulos, J., Narod, S. A., McLaughlin, J. R., Anton-Culver, H., Ziogas, A., Pearce, C. L., Wu, A. H., Lindström, S. & Terry, K. L., Jan 1 2019, In : International journal of epidemiology. 48, 3, p. 822-830 9 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Open Access
Polycystic Ovary Syndrome
Random Allocation
Ovarian Neoplasms
Odds Ratio
Confidence Intervals

Gynecologic cancer screening in the transgender male population and its current challenges

Patel, J. M., Dolitsky, S., Bachman, G. A. & Buckley De Meritens, A., Nov 1 2019, In : Maturitas. 129, p. 40-44 5 p.

Rutgers, The State University

Research output: Contribution to journalReview article

Transgender Persons
Early Detection of Cancer
Screening
Insurance
Visibility

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Stein, M. N., Malhotra, J., Tarapore, R. S., Malhotra, U., Silk, A. W., Chan, N., Rodriguez-Rust, L., Aisner, J., Aiken, R. D., Mayer, T., Haffty, B. G., Newman, J. H., Aspromonte, S. M., Bommareddy, P. K., Estupinian, R., Chesson, C. B., Sadimin, E. T., Li, S., Medina, D. J., Saunders, T. & 14 others, Frankel, M., Kareddula, A., Damare, S., Wesolowsky, E., Gabel, C., El-Deiry, W. S., Prabhu, V. V., Allen, J. E., Stogniew, M., Oster, W., Bertino, J. R., Libutti, S. K., Mehnert, J. M. & Zloza, A., May 22 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 136.

Rutgers, The State University

Research output: Contribution to journalArticle

Open Access
Oral Administration
Safety
Neoplasms
Pharmacokinetics
TIC10 compound